iCAD Appoints R. Scott Areglado As Chief Financial Officer
NASHUA,
N.H. — May 6, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today appointed R. Scott
Areglado as Chief Financial Officer. Mr.
Areglado has been serving as interim Chief Financial Officer since December
2018, and previously held the role of Corporate Controller at iCAD since May
2011.
“Scott has
consistently demonstrated the vision and leadership we sought for this role,
and we are pleased to appoint him as Chief Financial Officer,” said Michael
Klein, Chairman and Chief Executive Officer.
“Scott’s financial expertise has been instrumental as we’ve executed on
the appropriate infrastructure investments to support the successful U.S.
commercial launch of ProFound AI™, our latest, deep-learning, cancer detection
software solution for digital breast tomosynthesis. We look forward to further significant
contributions from Scott as our business continues to grow.”
Mr. Areglado has served as interim
Chief Financial Officer since December 2018.
Prior to this, he was Vice President and
Corporate Controller from May 2011, and previously held the role of interim
Chief Financial Officer from September 2016 to November 2016. From 2005 to
2010, Mr. Areglado served as Vice President and Controller at AMICAS, Inc., a
NASDAQ-listed image and information management solutions company serving the
healthcare industry, where he led the financial statement preparation and
accounting operations for the company, including support for the successful
acquisition of the company by Merge Healthcare. Mr. Areglado has more than 25
years of experience in finance and accounting and was a Certified Public
Accountant from 1990 to 2007. He received a Master of Business Administration
degree from the Franklin W. Olin Graduate School of Business at Babson College
and a Bachelor of Business Administration degree in Accounting from the
University of Massachusetts, Amherst.
About iCAD, Inc.
Headquartered in Nashua, N.H., iCAD is a global
medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit www.icadmed.com.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995
Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited, to the
Company’s ability to achieve business and strategic objectives, the risks of
uncertainty of patent protection, the impact of supply and manufacturing
constraints or difficulties, uncertainty of future sales levels, protection of
patents and other proprietary rights, the impact of supply and manufacturing
constraints or difficulties, product market acceptance, possible technological
obsolescence of products, increased competition, litigation and/or government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,”
“continue,” “anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contact:
Media
Inquiries:
iCAD, Inc.
603.882.5200
or
Investor
Relations:
LifeSci
Advisors
Jeremy
Feffer
(212)
915-2568